Table 28Study information table for trials of acetylcholinesterase inhibitors or memantine versus placebo in people with AD – non-cognitive symptoms of dementia

Acetylcholinesterase inhibitor (donepezil) versus placebo for ADAcetylcholinesterase inhibitor (galantamine) versus placebo for ADMemantine versus placebo for AD
Total no. of trials (total no. of participants)5 (1,082)2 (1,364)3 (1,005)
Study ID (drug)FELDMAN2001
HOLMES2004
NUNEZ2003
TARIOT2001A
WINBLAD2001B
ROCKWOOD2001
TARIOT2000
MD-01
PESKIND2006
REISBERG 2003
DiagnosisADADAD
Diagnostic toolNINDS-ADRDANINDS-ADRDANINDS-ADRDA
Treatment length: mean range12 to 52 weeks12 to 21 weeks24 to 28 weeks
Age (years): mean range72 to 8675 to 7875 to 77

From: 8, THERAPEUTIC INTERVENTIONS FOR PEOPLE WITH DEMENTIA – NON-COGNITIVE SYMPTOMS AND BEHAVIOUR THAT CHALLENGES

Cover of Dementia
Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care.
NICE Clinical Guidelines, No. 42.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2007.
Copyright © 2007, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.